Overall survival according to EBMT transplantation risk score
. | 5-y overall survival, % . | . | . | ||
|---|---|---|---|---|---|
| . | . | CIBMTR series . | . | ||
| Total risk score . | EBMT series . | All patients . | ECP patients . | ||
| 0-1 | 72 | 69 | 70 | ||
| 2 | 62 | 63 | 67 | ||
| 3 | 48 | 44 | 50 | ||
| 4 | 40 | 26 | 29 | ||
| 5-7 | 22 | 11 | 25 | ||
. | 5-y overall survival, % . | . | . | ||
|---|---|---|---|---|---|
| . | . | CIBMTR series . | . | ||
| Total risk score . | EBMT series . | All patients . | ECP patients . | ||
| 0-1 | 72 | 69 | 70 | ||
| 2 | 62 | 63 | 67 | ||
| 3 | 48 | 44 | 50 | ||
| 4 | 40 | 26 | 29 | ||
| 5-7 | 22 | 11 | 25 | ||
All EBMT and CIBMTR patients were treated by conventional alloHSCT procedures between 1989 and 1997. Leukemia-free survival (calculated only in the EBMT study) at 5 years was 61% for risk scores 0-1, 47% for risk score, 2, 37% for risk score 3, 35% for risk score 4, and 19% for risk scores 5-7.